MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$200.10
−1.25%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$196.69
From 52W high−18.60%
Volume21.42M
Market cap$79.89B
P/E (TTM)—
P/S (TTM)35.9x
Div yield—
Key dataOct 23, 2026
Open
$196.69
From 52W high
−18.60%
Volume
21.42M
Market cap
$79.89B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.9x
P/E (TTM)
—
RSI (14)
52.2
MomentumView details →
1D Return
−1.25%
YTD Return
+600.19%
SummaryUpdated Jun 1, 2026
Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company went public in December 2018 and gained global prominence during the COVID-19 pandemic as one of the first companies to develop and commercialize an mRNA-based vaccine. Originally founded as Moderna Therapeutics, the company changed its name to Moderna, Inc. in August 2018. Today, Moderna has evolved from a single-product COVID vaccine company into a multi-product biotechnology firm with an expanding pipeline of mRNA-based therapeutics and vaccines across multiple disease areas.
Similar companies
Latest newsMore news →
Moderna, Inc.'s stock dropped after study details raised questions about the potential use of its cancer vaccine.6h agoModerna, Inc. shares fell late Thursday and were weak Friday morning before recovering their losses and trading higher later in the session.11h agoModerna, Inc. shares fell 20% over two days after a partial leak of positive cancer-vaccine trial results.14h ago